PAGE FOR USERS

Investor & strategic partnership opportunity

GaiaCell represents a strategically positioned platform company in the Advanced Therapy Medicinal Products (ATMP) sector, combining proprietary cell and gene therapy technologies, GMP manufacturing infrastructure, and fully integrated CDMO capabilities.

The company operates across development, manufacturing, and clinical translation, enabling both value creation through internal programmes and scalable partnership-driven growth.

Establish Collaboration


Investment Thesis

An investment in GaiaCell provides exposure to the rapidly expanding ATMP and cell & gene therapy market, an integrated platform combining R&D, manufacturing, and services, reduced binary risk through diversified assets and CDMO operations, opportunities for strategic control, regional expansion, and long-term industrial collaboration

GaiaCell seeks partners who share a long-term vision for building compliant, scalable, and locally deployable advanced therapy solutions.

NAŠE CDMO STORITVE

Strategic Rationale

The global ATMP market is characterised by high technological complexity, regulatory barriers, and significant capital requirements for GMP infrastructure. GaiaCell addresses these challenges through an integrated model that combines:

  • In-house R&D across multiple advanced therapy modalities
  • GMP-compliant manufacturing and quality systems
  • CDMO services generating near- and mid-term revenues
  • Structured technology transfer and partnership frameworks enabling local deployment and partner independence

This model positions GaiaCell as both a technology owner and a platform enabler, reducing dependency on single-asset risk and supporting diversified value creation.

NAŠ PRISTOP

Partnership & Investment Models

GaiaCell is open to flexible collaboration and investment structures, including:

  • Strategic equity investment aligned with long-term industrial cooperation
  • Platform-level partnerships (e.g. MSC, CAR-T, lentiviral vectors, TIL)
  • Co-development and risk-sharing models for selected R&D programmes
  • Regional or national deployment partnerships for ATMP manufacturing and clinical implementation
  • CDMO-based commercial collaborations with conversion potential into deeper strategic alignment

Partnership structures can be tailored to investor objectives, including access to technology, manufacturing capacity, regional exclusivity, or downstream commercial participation.

CLINICAL AND STRATEGIC SIGNIFICANCE

Value Creation Drivers

GaiaCell’s approach emphasises long-term sustainability, regulatory robustness, and operational control rather than short-term transactional growth.

Key value drivers for investors and strategic partners include:

1
Proprietary technology platforms across MSC-based therapies, immuno-oncology, and exosome development
2
Validated GMP manufacturing capabilities, reducing time and capital required to enter ATMP markets
3
CDMO revenue generation, providing cash-flow support alongside pipeline development
4
High regulatory and operational barriers to entry, supporting defensible positioning
5
Scalable and transferable operating model, enabling geographic and therapeutic expansion

NAŠE CDMO STORITVE

Strategic Rationale

GaiaCell maintains a diversified R&D portfolio at different stages of maturity, including:

  • CAR-T cell therapy platform with proprietary vector systems,
  • Tumour-Infiltrating Lymphocyte (TIL) therapy programme for solid tumours,
  • Exosome-based therapeutic research and
  • Regenerative medicine programmes based on MSC platforms

These programmes provide optionality for value inflection through partnering, spin-outs, or late-stage development, depending on strategic alignment.

INVESTMENT OVERVIEW

Integrated ATMP Platform & CDMO

For investors seeking a deeper understanding of GaiaCell’s technology, market opportunity, and growth strategy.

Sector
faster transition from development to clinical use
Focus
greater reproducibility and reliability of manufacturing processes
Geography
better alignment with real-world clinical needs
Company Overview
GaiaCell is an integrated ATMP platform company combining proprietary cell and gene therapy technologies, GMP-compliant manufacturing infrastructure, and full CDMO capabilities. The company operates across the advanced therapy value chain, from early development and clinical translation to commercial manufacturing and partner enablement.
GaiaCell’s business model integrates internal R&D programmes with revenue-generating CDMO services, enabling diversified value creation and reduced single-asset risk.
Core Capabilities
Cell Therapy Platforms
o Autologous and allogeneic MSC-based platforms
o Regenerative medicine and   immunomodulatory applications
Immuno-Oncology R&D
o CAR-T platform with proprietary lentiviral vector systems
o Tumour-Infiltrating Lymphocyte (TIL) therapy programme
Manufacturing & CDMO
o GMP manufacturing of cell and gene therapies
o Process development, scale-up, and technology transfer
Cryo-Biobanking & Allografts
o Cryopreservation services and regulated tissue distribution
Core Capabilities
Cell Therapy Platforms
o Autologous and allogeneic MSC-         based platforms
o Regenerative medicine and   immunomodulatory applications
Immuno-Oncology R&D
o CAR-T platform with proprietary     lentiviral vector systems
o Tumour-Infiltrating Lymphocyte (TIL)  therapy programme

Manufacturing & CDMO
o GMP manufacturing of cell and gene therapies
o Process development, scale-up, and technology transfer
Cryo-Biobanking & Allografts
o Cryopreservation services and regulated tissue distribution
Business Model
1
CDMO services generating near- to mid-term revenues
2
Platform partnerships and co-development opportunities
3
Technology transfer and local deployment models
4
Long-term strategic partnerships and equity participation

NAŠE CDMO STORITVE

Investment Highlights

  • Integrated ATMP platform across R&D, GMP, and CDMO
  • High regulatory and technical barriers to entry
  • Diversified pipeline reducing binary development risk
  • Scalable and transferable operating model
  • Strong alignment with EU and global ATMP market growth
Investment Opportunity
GaiaCell is seeking strategic equity investment and long-term industrial partnerships to support platform expansion, 
GMP capacity scaling, and advancement of selected R&D programmes.

Strategic Fit – Pharma / MedTech / Hospital Groups

Why GaiaCell is a Strategic Partner
GaiaCell is positioned as a technology and manufacturing partner rather than a single-product biotech. Its integrated ATMP platform enables strategic partners to access advanced therapy capabilities while retaining long-term operational and strategic control.
Strategic Fit by Partner Type
Pharmaceutical Companies

Strategic Value

  • Accelerated entry into cell & gene therapy without full internal build-out
  • Access to GMP manufacturing and validated ATMP quality systems
  • Platform-level collaboration rather than single-asset exposure

Use Cases

  • CAR-T or cell therapy pipeline acceleration
  • Lentiviral vector development and manufacturing
  • Hybrid models combining internal R&D with external GMP capacity
MedTech Companies

Strategic Value

  • Expansion from devices to biologics and combination products
  • Integration of cell-based therapies with implants, scaffolds, or delivery systems
  • Lower regulatory and manufacturing barriers through partnership

Use Cases

  • Orthopedics and regenerative medicine solutions
  • Combination products (cells + biomaterials)
  • Co-development of next-generation regenerative platforms
Hospital Groups & Clinical Networks

Strategic Value

  • Access to GMP-compliant ATMP manufacturing
  • Capability building for in-house or regional advanced therapies
  • Reduced dependency on external suppliers over time

Use Cases

  • Hospital-based ATMP programmes
  • Local manufacturing and clinical translation
  • Training, technology transfer, and operational enablement

NAŠE CDMO STORITVE

Partnership Models

  • Strategic equity participation
  • Co-development and risk-sharing programmes
  • CDMO manufacturing with stepwise capability transfer
  • Regional or national ATMP deployment partnerships

Each model is designed to align commercial supply, technology access, and long-term partner independence, where appropriate.

Strategic Outcome
Partnership with GaiaCell enables pharma, medtech, and hospital groups to:
1
Enter or expand within the ATMP space efficiently
2
Reduce capital and regulatory risk
3
Build sustainable, compliant, and locally deployable advanced therapy capabilities
Read more

Looking for a Reliable Partner?

Contact with us and let us work together to find the optimal solution for your project or clinical practice.

Establish Collaboration
crossmenu